Drug
Solriamfetol Dose A
Solriamfetol Dose A: highest development phase Phase 3, developed by Axsome Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Axsome Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Solriamfetol Dose A NCT07717892 | Phase 3 | ADHD |
| Solriamfetol Dose A NCT07717879 | Phase 3 | ADHD |
Latest
No recent events.
Follow Solriamfetol Dose A on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.